Trials / Terminated
TerminatedNCT02966002
Aspirin as a Novel Anti-Inflammatory Modality in the Fontan Patients
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- University of Michigan · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients who have undergone the Fontan procedure (a congenital heart surgery) may develop complications many years after their operation. Studies have shown that some of these patients develop an ongoing inflammatory state, which may be the cause of these late complications. Aspirin is a common over the counter anti-inflammatory medication used for many other chronic diseases. This study may help determine if aspirin therapy can limit the inflammation seen in Fontan patients and prevent these late complications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aspirin |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2017-05-25
- Completion
- 2017-05-25
- First posted
- 2016-11-17
- Last updated
- 2018-05-18
- Results posted
- 2018-05-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02966002. Inclusion in this directory is not an endorsement.